FDA Advisors Want More Data On Nanotech Sunscreens
This article was originally published in The Rose Sheet
Members of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology say more light needs to be shed on nanotechnology. FDA officials tell the panel the agency’s understanding of how pharmaceutical firms are using nanotechnology is still developing, but they maintain that currently marketed products are safe.
You may also be interested in...
FDA's draft guidance to industry suggesting that ingredients up to 1 micrometer in size still qualify as nanomaterials if they exhibit “altered properties” should be revised to avoid confusion in the marketplace and promote international harmonization, according to the Personal Care Products Council.
National Center for Toxicological Research signs agreement setting up CERS in Arkansas.
As early as June 2012, sunscreens that fail “broad spectrum” tests or have an SPF less than 15 must warn that they have not been shown to prevent cancer or early skin aging, according to an FDA final rule.